Charles S. Berkman
2020 - Ligand Pharmaceuticals
In 2020, Charles S. Berkman earned a total compensation of $1.9M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 4% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $176,767 |
---|---|
Option Awards | $675,820 |
Salary | $441,917 |
Stock Awards | $644,168 |
Other | $6,180 |
Total | $1,944,852 |
Berkman received $675.8K in option awards, accounting for 35% of the total pay in 2020.
Berkman also received $176.8K in non-equity incentive plan, $441.9K in salary, $644.2K in stock awards and $6.2K in other compensation.
Rankings
In 2020, Charles S. Berkman's compensation ranked 5,646th out of 13,090 executives tracked by ExecPay. In other words, Berkman earned more than 56.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,646 | 57th |
Manufacturing | 2,331 | 59th |
Chemicals And Allied Products | 930 | 59th |
Drugs | 804 | 59th |
Pharmaceutical Preparations | 598 | 59th |
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2020.